Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus, to enable unprecedented precision in targeting aggressive cancers
IQ Capital, Cancer Research Horizons, National Brain Tumor Society, AIN Ventures and Old College Capital now also investors in Trogenix
Dr Ken Macnamara, a veteran gene therapy executive who held leadership roles at Bayer/AskBio and Synpromics, appointed as Chief Executive Officer
Tay Salimullah, former executive team member at Novartis Gene Therapies, joins the Board as Trogenix advances towards clinical development
